AIDS 2026 | Dr. Bascombe: Moving Beyond BMI to Address Occult Liver Injury in Lean HIV-Associated Fatty Liver Disease

AIDS 2026 | Dr. Bascombe: Moving Beyond BMI to Address Occult Liver Injury in Lean HIV-Associated Fatty Liver Disease

The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil. Bringing together global specialists in infectious diseases, the conference covered a wide array of cutting-edge topics including viral prevention and control, antiretroviral therapy, and long-term health management for people living with HIV, and shared numerous innovative clinical research findings. At the conference, Dr. Florence Bascombe from University College London presented a special study on lean steatotic liver disease (SLD) among people living with HIV. Her discoveries have reshaped established clinical understanding of disease characteristics in patients with lean fatty liver disease, offering new insights into liver disease screening and management for this special population.
AIDS 2026 | Dr. Alfredo Tagarro: Moving Beyond Transmission – In-Depth Exploration of Immune Profiles and Intervention Strategies in HIV-Exposed Infants and Young Children

AIDS 2026 | Dr. Alfredo Tagarro: Moving Beyond Transmission – In-Depth Exploration of Immune Profiles and Intervention Strategies in HIV-Exposed Infants and Young Children

The 2026 International AIDS Conference (AIDS 2026) was successfully held in Rio de Janeiro, Brazil. The prevention and control of maternal, infant and pediatric HIV remained a key topic of discussion at this conference. We conducted an exclusive interview with Dr. Alfredo Tagarro from the Instituto de Investigación 12 de Octubre, Spain. Breaking free from the conventional analytical framework of mother-to-child transmission, his research proposes an innovative research perspective of “Moving Beyond Transmission”, focusing on immune characteristics, risk triggers and intervention strategies among HIV-exposed infants and young children. The in-depth discussion covers core directions including pediatric immune disparities, gaps in clinical screening, and pre-emptive family interventions, delivering cutting-edge research insights to optimize full-cycle health management for HIV-exposed infants and young children.
2026 Pujiang Urological Oncology Academic Conference丨Professor Dingwei Ye: Reshaping First-Line Treatment for Urothelial Carcinoma — Standardized Comprehensive Management to Maximize Long-Term Patient Benefit

2026 Pujiang Urological Oncology Academic Conference丨Professor Dingwei Ye: Reshaping First-Line Treatment for Urothelial Carcinoma — Standardized Comprehensive Management to Maximize Long-Term Patient Benefit

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. In recent years, innovative approaches including antibody-drug conjugates (ADCs), immunotherapy, and precision diagnostics have developed rapidly, shifting the treatment goals of urothelial carcinoma from short-term disease control toward deeper responses, long-term survival, and comprehensive disease management. Enfortumab vedotin-based combination therapy has changed the first-line treatment standard for locally advanced or metastatic urothelial carcinoma (LA/mUC). At the same time, patient selection, standardized treatment, adverse event management, response assessment, and long-term follow-up in real-world practice have become critical to translating evidence-based benefits into meaningful clinical outcomes. Oncology Frontier · UroStream invited Professor Dingwei Ye of Fudan University Shanghai Cancer Center to share his clinical perspectives on first-line treatment transformation, standardized continuous treatment, and advances in perioperative research.
From Evidence to Clinical Practice丨FRUSICA-2 Case Series in Second-Line Treatment of Advanced Renal Cell Carcinoma Officially Released

From Evidence to Clinical Practice丨FRUSICA-2 Case Series in Second-Line Treatment of Advanced Renal Cell Carcinoma Officially Released

Building on the evidence from the pivotal FRUSICA-2 registration study, the FRUSICA-2 Case Series has now been officially launched. This case collection brings together real-world clinical cases from multiple centers across China, providing practical insights into the clinical application of fruquintinib plus sintilimab as second-line treatment for advanced renal cell carcinoma. Scan the QR code to access the complete case collection.
Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

In recent years, with the continued advancement of precision medicine, PARP inhibitors have assumed an increasingly important role in prostate cancer treatment, particularly among patients harboring homologous recombination repair (HRR) gene alterations, in whom they have demonstrated clear clinical benefits. At the same time, a range of combination strategies involving PARP inhibitors and androgen receptor pathway inhibitors (ARPIs), immunotherapy, chemotherapy, and other treatment modalities have emerged, ushering advanced prostate cancer into an era of combination therapy. However, despite the rapid accumulation of clinical evidence, questions remain regarding the optimal treatment sequence, differences in benefit across specific HRR mutation subtypes, and strategies for managing resistance in the setting of combination therapy. Further evidence is needed to clarify these issues.
2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts in urological oncology from China and abroad to discuss standardized diagnosis and treatment, surgical innovation, and advances in precision medicine. Upper tract urothelial carcinoma (UTUC) complicated by inferior vena cava (IVC) tumor thrombus is relatively rare and is associated with substantially increased surgical complexity and perioperative risk. Oncology Frontier · UroStream invited Professor Shudong Zhang of Peking University Third Hospital for an interview, during which he shared his team's experience and clinical perspectives on preoperative imaging assessment and risk stratification, the application of robotic surgery, and multidisciplinary team (MDT) management throughout the treatment journey.
2026 Pujiang Urological Oncology Academic Conference丨Nan Liu: Precision Strategies for Robot-Assisted Partial Nephrectomy of Completely Endophytic Renal Tumors—from Preoperative 3D Planning to Intraoperative Localization and Nephron-Sparing Decision-Making

2026 Pujiang Urological Oncology Academic Conference丨Nan Liu: Precision Strategies for Robot-Assisted Partial Nephrectomy of Completely Endophytic Renal Tumors—from Preoperative 3D Planning to Intraoperative Localization and Nephron-Sparing Decision-Making

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urological oncology. Completely endophytic renal tumors are particularly challenging because they lack visible landmarks on the renal surface, making intraoperative localization, margin control, and preservation of the collecting system and renal vasculature difficult. Oncology Frontier – UroStream invited Professor Nan Liu of Chongqing University Cancer Hospital for an interview to discuss preoperative assessment, intraoperative localization and tumor resection strategies, and nephron-sparing decision-making for highly complex renal tumors, sharing his clinical experience and perspectives on surgical techniques.
The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

Bringing together leading experts in the field, the 14th Lu Daopei Hematology Forum opened on August 21, 2026, at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year’s conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic disorders. The conference brought together leading experts and scholars from across China to discuss the future development of hematology and served as an important platform for advancing the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Huili Zhu from Lu Daopei Hospital to share her insights into the updated 7th edition of the guidelines for invasive fungal disease (IFD) in patients with hematologic disorders, focusing on the background of the update, key changes, and strategies for clinical implementation.
The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wang of Lu Daopei Hospital for an exclusive interview. She shared her professional insights on the opportunities and challenges facing laboratory diagnosis of hematologic diseases in the era of precision medicine, the value of multidisciplinary collaboration, and the prospects for artificial intelligence applications.
The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Peihua Lu of Lu Daopei Hospital for an exclusive interview. She shared her insights into the highlights of this year's conference, the value of the academic platform, and the role of multidisciplinary collaboration and research in advancing clinical practice.